Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Recruiting · NCT06029309 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-21 | NCT06029309 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alvaro Alencar, MD | 1 |
| BeOne Medicines | 76 |
| Incyte Corporation | 153 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Miami | Miami | United States | 327 |